Product Description
Pentoxifylline is a drug used in the management of the peripheral vascular disease. It is a xanthine derivative. Pentoxifylline and its metabolites decrease blood viscosity and improve blood flow and peripheral tissue oxygenation. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK559096/)
Mechanisms of Action: PDE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CSPC Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Neonatal Sepsis
Phase 2: Behcet Syndrome|Lung Injury|Non-Small-Cell Lung Cancer|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| P4-PACIFIC | P2 |
Not yet recruiting |
Pneumonia|Lung Injury|Non-Small-Cell Lung Cancer |
2030-11-30 |
|
| P145440V01A | P2 |
Not yet recruiting |
Behcet Syndrome |
2024-11-01 |
49% |
| Pentoxifylline in neonatal sepsis | P3 |
Active, not recruiting |
Neonatal Sepsis |
2021-03-10 |